Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 906349, 10 pages
http://dx.doi.org/10.1155/2015/906349
Clinical Study

The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

1Translational Development, Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA
2Biostatistics, Celgene Corporation, 33 Technology Drive, Warren, NJ 07059, USA

Received 26 September 2014; Accepted 10 January 2015

Academic Editor: Marco Antonio Velasco-Velázquez

Copyright © 2015 Peter H. Schafer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Peter H. Schafer, Peng Chen, Lorraine Fang, Andrew Wang, and Rajesh Chopra, “The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1),” Journal of Immunology Research, vol. 2015, Article ID 906349, 10 pages, 2015. https://doi.org/10.1155/2015/906349.